Table 2 Results from the WISCA model for all blood cultures included: percentage, BUI (Bayesian Uncertainty Intervals)
Guidelines for the management of FN | Estimated coverages of studied regimens from WISCA model |
|---|---|
Use monotherapy with an antipseudomonal b-lactam, a fourth-generation cephalosporin or a carbapenem as empiric antibacterial therapy in pediatric high-risk FN (strong recommendation, high-quality evidence) Reserve addition of a second anti-Gram-negative agent or a glycopeptide for patients who are clinically unstable, when a resistant infection is suspected, or for centres with a high rate of resistant pathogens (strong recommendation, moderate-quality evidence) | Antipseudomonal b-lactam: 75% (0,28–0,89) Carbapenem: 83% (0,38–0,93) Anti-pseudomonal + second anti-gram negative: 78% (0,11–0,94) Carbapenem + second anti-gram negative: 78% (0,13–0,94) Anti-pseudomonal + second anti-gram negative + glycopeptide: 97% (0,03–0,99) Carbapenem + second anti-gram negative + glycopeptide: 97% (0,03–0,99) |